What percentage of bakuchiol actually works?

The entire evidence base for bakuchiol efficacy rests on one well-designed but small trial. Dhaliwal et al. 2019 (British Journal of Dermatology) randomized 44 participants with facial photoaging to either 0.5% bakuchiol cream twice daily or 0.5% retinol cream once daily for 12 weeks. Both groups showed significant reductions in wrinkle surface area and hyperpigmentation within their own groups. No statistically significant difference was found between the two compounds on those outcomes. Retinol users reported significantly more facial scaling and stinging. What this study does and does not tell you: it shows that 0.5% bakuchiol twice daily produces measurable photoaging improvements in a 12-week window and is better tolerated than retinol at an equivalent concentration. It does not establish that bakuchiol is equivalent to retinol — the design found no statistically significant difference between groups, but a formal non-inferiority analysis was not conducted. With n=44, the study was not powered to detect small between-group differences. One small trial is not proof of equivalence; it is an encouraging signal that warrants larger replication.

• Study In a 12-week randomized, double-blind trial (n=44), 0.5% bakuchiol cream twice daily and 0.5% retinol cream once daily both significantly reduced wrinkle surface area and hyperpigmentation; no statistically significant difference was found between the two compounds on those outcomes. ¹
• Study Retinol users experienced significantly more facial skin scaling and stinging than bakuchiol users in the Dhaliwal 2019 RCT; bakuchiol was rated as 'better tolerated than retinol.' ¹

The cosmetic industry uses bakuchiol at 0.5–2%, with most products clustering at 0.5–1%. The 0.5% anchor makes sense: it is the only published RCT dose, and it is a reasonable starting point for a tolerability-first ingredient. Products at 1% or 2% are common in the market but no published peer-reviewed dose-finding study characterizes how efficacy or tolerability changes across this range. There is no saturation or ceiling study analogous to the percutaneous absorption work that established optimal vitamin C concentrations. 'More is better' cannot be assumed — and because bakuchiol is not a retinoid, the retinoid literature on dose-response does not transfer. The Chaudhuri & Bojanowski 2014 study — the other major reference in the category — conducted a 12-week clinical application study showing improvements in lines, wrinkles, pigmentation, and elasticity alongside gene expression evidence of collagen pathway upregulation. That study used concentrations consistent with cosmetic practice. However, it was conducted by researchers affiliated with the ingredient supplier, and independent academic replication is limited.

• Study The Dhaliwal 2019 RCT used 0.5% bakuchiol twice daily — the only published RCT-tested dose — and found significant improvement in wrinkles and hyperpigmentation over 12 weeks. ¹
• Study The Chaudhuri & Bojanowski 2014 study reported significant improvements in lines, wrinkles, pigmentation, elasticity, and firmness after 12 weeks of twice-daily application, alongside gene expression evidence that bakuchiol upregulates types I, III, and IV collagen via retinol-like pathways. ²

One honest caveat The Chaudhuri 2014 study was conducted by researchers affiliated with the ingredient supplier (Sytheon). Independent academic replication of the full collagen and anti-aging findings is limited. The dose-response relationship across the 0.5–2% commercial range has not been characterized in independent peer-reviewed literature.

Bakuchiol is a meroterpene phenol isolated from the seeds of Psoralea corylifolia (babchi plant). It contains no ring or polyene chain structure characteristic of retinoids. It is chemically unrelated to retinol, retinoic acid, or vitamin A. The 'natural retinol' label is a functional analogy, not a chemical or pharmacological one. The functional similarity is real: gene expression profiling demonstrates that bakuchiol upregulates types I, III, and IV collagen and produces a retinol-like signature in skin models. But the mechanism is different — bakuchiol does not bind retinoic acid receptors (RARs) the way retinoids do, and the alternative signaling pathway is not fully elucidated. This distinction matters when evaluating safety claims (including pregnancy safety) and when comparing to prescription retinoids: bakuchiol's evidence base is its own, not borrowed from the retinoid literature.

• Study Bakuchiol is a meroterpene phenol from Psoralea corylifolia seeds. It is structurally unrelated to retinol and does not belong to the retinoid chemical class. Gene expression profiling showed it upregulates types I, III, and IV collagen and produces a retinol-like overall gene expression signature despite lacking retinoid structure. ²

The tolerability advantage over retinol is the most robustly supported claim in the category. The Dhaliwal 2019 RCT found statistically significantly less facial scaling and stinging in the bakuchiol group versus retinol. The Chaudhuri 2014 study reported the absence of typical retinol-associated undesirable effects in their clinical application group. Practically, this means bakuchiol is a reasonable option for people who have struggled with retinol's initial adjustment period — dryness, flaking, and photosensitivity. It does not require the tolerance-building titration commonly recommended when starting retinol or retinoids. Whether the tolerability benefit extends to all skin types and to longer timeframes than 12 weeks is untested in the published literature.

• Study In the Dhaliwal 2019 RCT, retinol users experienced significantly more facial skin scaling and stinging than bakuchiol users over 12 weeks. ¹
• Study The Chaudhuri 2014 12-week clinical application study reported improvements in photoaging markers without 'usual retinol therapy-associated undesirable effects.' ²

Bakuchiol is heavily marketed as a 'pregnancy-safe retinol alternative.' This framing reflects a real and important distinction: bakuchiol is not a retinoid and does not carry the vitamin A-related teratogenicity concern that makes prescription retinoids contraindicated in pregnancy. That is a meaningful difference. But absence of retinoid risk is not the same as established safety. No human safety or pharmacokinetic data for bakuchiol in pregnancy has been published. The source plant Psoralea corylifolia contains psoralens — phototoxic furocoumarins — that are structurally distinct from bakuchiol but present in crude babchi preparations. Purified bakuchiol isolate as used in cosmetics is separated from these compounds, but formulation-specific purity is not uniformly verified. The appropriate guidance is: not expected to carry retinoid teratogenicity risk, but affirmative pregnancy safety has not been established. Discuss any new topical active with your doctor or midwife during pregnancy.

• Review Psoralea corylifolia seeds contain psoralens (furocoumarins) including psoralen, isopsoralen, and angelicin, which are phototoxic and structurally distinct from bakuchiol. Purified bakuchiol isolates are separate from these compounds. ³

One honest caveat No human safety data for bakuchiol in pregnancy exists in peer-reviewed literature. The 'pregnancy-safe' label reflects absence of retinoid teratogenicity risk, not affirmative evidence. Always consult a healthcare provider before starting new topicals during pregnancy.

Bakuchiol's evidence base is thin by the standards of well-studied cosmetic ingredients. Key gaps: — One RCT. The entire equivalence-to-retinol narrative rests on a single 44-person, 12-week trial (Dhaliwal 2019). There is no larger replication, no long-term study beyond 12 weeks, and no data across different skin types or ethnicities beyond that one study population. — No dose-response data. Whether 1% or 2% outperforms 0.5% has never been tested in published peer-reviewed literature. The commercial range is extrapolated without dose-finding evidence. — No CIR safety assessment. The Cosmetic Ingredient Review has not published a safety assessment for bakuchiol as of this review. — Photostability is plausible, not quantified. Industry marketing claims bakuchiol is photostable relative to retinol, permitting AM use. This is consistent with its phenolic chemical structure and with the Dhaliwal protocol (bakuchiol group used it twice daily). But a 2023 peer-reviewed photoreactivity study was unable to conclusively assess bakuchiol's photostability due to assay limitations. Direct quantification under standardized cosmetic UV conditions is lacking. — Conflict-of-interest density. The Chaudhuri & Bojanowski 2014 paper — the mechanistic backbone of the entire category — was authored by researchers affiliated with Sytheon, the ingredient supplier. Independent academic replication is limited.

• Study A 2023 comparative photoreactivity study was unable to conclusively assess bakuchiol's photostability due to limitations of the ROS assay used; the degree of bakuchiol photostability remains unquantified in that study. ⁴
• Review A 2022 systematic review of bakuchiol's applications in dermatology (Puyana, Chandan, Tsoukas) surveyed the published evidence base and the limited trial count within it. ⁵

What percentage of bakuchiol actually works?

0.5% twice daily is the concentration tested in the only published RCT (Dhaliwal et al. 2019, n=44, 12 weeks) and showed significant improvements in wrinkles and hyperpigmentation comparable to 0.5% retinol. Most products formulate at 0.5–1%, which sits closest to that tested dose. Whether higher concentrations (1–2%) do more has not been studied in published peer-reviewed literature — there is no dose-response data across the commercial range. ¹

Is bakuchiol as effective as retinol?

The Dhaliwal 2019 RCT (n=44, 12 weeks) found no statistically significant difference between 0.5% bakuchiol twice daily and 0.5% retinol once daily for wrinkles and hyperpigmentation. That is an encouraging result, but it is one small trial and a formal non-inferiority analysis was not conducted. It would be an overstatement to call bakuchiol 'proven equivalent to retinol' — the accurate reading is that it produced comparable outcomes in one well-designed small study, with better tolerability. ¹

Is bakuchiol actually a retinol?

No. Bakuchiol is a meroterpene phenol — it is chemically unrelated to retinol, retinoids, or vitamin A. It produces retinol-like functional effects on skin gene expression and collagen pathways, which is why it is called a 'functional analogue.' The phrase 'natural retinol' is marketing shorthand for this functional similarity, not a statement of chemical or pharmacological equivalence. ²

Is bakuchiol safe to use in pregnancy?

Bakuchiol is not a retinoid and does not carry the vitamin A-related teratogenicity concern that makes prescription retinoids contraindicated in pregnancy — that distinction is real and matters. However, affirmative pregnancy safety has not been established: no human safety data for bakuchiol in pregnancy has been published. The source plant contains psoralens (phototoxic compounds distinct from bakuchiol), though purified bakuchiol isolate is separated from these. The 'pregnancy-safe' label reflects absence of one specific risk, not confirmed safety. Discuss with your doctor or midwife before use. ³

Can I use bakuchiol in the morning?

Bakuchiol is widely considered photostable relative to retinol, making AM use theoretically sound. The Dhaliwal 2019 protocol used bakuchiol twice daily (implying AM + PM use). However, peer-reviewed quantification of bakuchiol's photostability under standardized UV conditions is limited — a 2023 photoreactivity study was unable to conclusively assess it due to assay limitations. Use SPF regardless, as you should with any active targeting photoaging. ¹⁴

Is bakuchiol the same as babchi oil?

No. Babchi oil is a crude extract from Psoralea corylifolia seeds containing bakuchiol alongside psoralens — phototoxic furocoumarins that can cause severe skin reactions under UV. Purified bakuchiol isolate, as used in evidence-based cosmetic formulations, is separated from these compounds. Check your ingredient label: 'bakuchiol (purified)' and 'babchi oil' are not interchangeable. ³

Does bakuchiol cause purging or irritation like retinol?

Clinical evidence suggests bakuchiol is better tolerated than retinol. In the Dhaliwal 2019 RCT, retinol users reported significantly more scaling and stinging than bakuchiol users over 12 weeks. Bakuchiol is not generally associated with the purging and dryness that characterize retinol introduction and does not require the tolerance-building titration recommended for retinoids. ¹²

1. 1

   Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing

   Dhaliwal S, Rybak I, Ellis SR, Notay M, Trivedi M, Burney W, Vaughn AR, Nguyen M, Reiter P, Bosanac S, Yan H, Foolad N, Sivamani RK · British Journal of Dermatology 180(2):289-296 · 2019

2. 2

   Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti-aging effects

   Chaudhuri RK, Bojanowski K · International Journal of Cosmetic Science 36(3):221-30 · 2014

3. 3

   Bakuchiol, a natural constituent and its pharmacological benefits

   Nizam NN, Mahmud S, Ark SMA, Kamruzzaman M, Hasan MK · F1000Research · 2023

4. 4

   Comparative Studies on the Photoreactivity, Efficacy, and Safety of Depigmenting Agents

   Mota S, Rosa GP, Barreto MC, Garrido J, Sousa E, Cruz MT, Almeida IF, Quintas C · Pharmaceuticals (Basel) 17(1):55 · 2023

5. 5

   Applications of bakuchiol in dermatology: Systematic review of the literature

   Puyana C, Chandan N, Tsoukas M · Journal of Cosmetic Dermatology · 2022